Europe Uterine Cancer Drug Market - Industry Trends and Forecast to 2030

Europe Uterine Cancer Drug Market - Industry Trends and Forecast to 2030

The Europe uterine cancer drugs market is expected to reach USD 1,251,870.80 thousand by 2030 from USD 684,672.98 thousand in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.
Market Segmentation
Europe Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End-User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe) – Industry Trends and Forecast to 2030
Overview of Europe Uterine Cancer Drugs Market Dynamics

Driver
• Rising incidence of uterine cancer

Restrain

• High cost of uterine cancer treatment

Opportunity

• Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Europe uterine cancer drugs market are:

• Merck & Co., Inc.
• Sanofi
• Eisai Co., Ltd.
• Pfizer Inc.
• Teva Pharmaceuticals USA, Inc.
• Baxter
• Hikma Pharmaceuticals PLC
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• GSK plc.
• Amneal Pharmaceuticals LLC.
• Getwell Oncology

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.